Praxis Precision Medicines Inc
PPR studies measure electroencephalogram (EEG) signatures after intermittent photic stimulation and are used as an indicator of anti-seizure efficacy.
“The strength and consistency of response across both study arms, combined with a continued positive tolerability and safety profile, build on our earlier conviction that PRAX-628 has the potential to be the first precision sodium channel modulator for focal epilepsy patients. With such a clear response, we have advanced our planning of the focal epilepsy efficacy study for PRAX-628, expected to begin in the second half of 2024,” said Marcio Souza, president and chief executive officer of Praxis.
- In the 15mg cohort, partial response was 20%, with complete response of 80%.
- In the 45mg, the complete response was 100%.
The Phase 2a study builds on results from animal studies and the Phase 1 dose escalation study in healthy volunteers.
- PRAX-628 demonstrated preclinical efficacy in the maximal electroshock seizure (MES) model.
- PRAX-628 was generally well-tolerated at all tested doses in the Phase 1 study.
- Pharmacokinetic data from the Phase 1 study demonstrated dose-dependent exposure supporting once-daily dosing without titration to achieve potentially therapeutically effective drug concentration levels.
- Further analysis of patients in the Phase 1 study using quantitative EEG data showed a pharmacodynamic effect at all dose levels and was significantly different from placebo.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.